Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: a multi-centre North London experience
Nalinie Joharatnam‐Hogan(MRC Clinical Trials Unit at UCL), Khurum Khan(Cancer Institute (WIA)), William Wilson(Cancer Research UK), Aun Muhammad(Whittington Hospital), Nikhil Vasdev(University of Hertfordshire), Anand Sharma(Mount Vernon Hospital), Valerie Crolley(North Middlesex Hospital), Hannah Rush(University College London), John Bridgewater(University College London Hospitals NHS Foundation Trust), Daniel Hochhauser(Royal London Hospital), Muhammad Naveed Anwar(Princess Alexandra Hospital NHS Trust), Aramita Saha(North Middlesex Hospital), Robert M. Goldstein(The Royal Free Hospital), Ganna Kantser(North Middlesex Hospital), Fharat Raja(North Middlesex Hospital), Kai‐Keen Shiu(University College London Hospitals NHS Foundation Trust)
Cited by 37
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k